Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy

Primo N Lara, Angela M. Davies, Philip Mack, Melinda M. Mortenson, Richard J Bold, Paul H. Gumerlock, David R Gandara

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 1
StatePublished - Feb 2004

Fingerprint

Proteasome Endopeptidase Complex
Lung Neoplasms
Therapeutics
Cyclins
Small Cell Lung Carcinoma
Ubiquitin
Multiple Myeloma
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Proteolysis
Lymphoma
Prostatic Neoplasms
Bortezomib
Radiation
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy. / Lara, Primo N; Davies, Angela M.; Mack, Philip; Mortenson, Melinda M.; Bold, Richard J; Gumerlock, Paul H.; Gandara, David R.

In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 1, 02.2004, p. 40-46.

Research output: Contribution to journalArticle

Lara, PN, Davies, AM, Mack, P, Mortenson, MM, Bold, RJ, Gumerlock, PH & Gandara, DR 2004, 'Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy', Seminars in Oncology, vol. 31, no. 1 SUPPL. 1, pp. 40-46.
Lara PN, Davies AM, Mack P, Mortenson MM, Bold RJ, Gumerlock PH et al. Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy. Seminars in Oncology. 2004 Feb;31(1 SUPPL. 1):40-46.
Lara, Primo N ; Davies, Angela M. ; Mack, Philip ; Mortenson, Melinda M. ; Bold, Richard J ; Gumerlock, Paul H. ; Gandara, David R. / Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy. In: Seminars in Oncology. 2004 ; Vol. 31, No. 1 SUPPL. 1. pp. 40-46.
@article{babf70f52666422eb05876041d108213,
title = "Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy",
abstract = "PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.",
author = "Lara, {Primo N} and Davies, {Angela M.} and Philip Mack and Mortenson, {Melinda M.} and Bold, {Richard J} and Gumerlock, {Paul H.} and Gandara, {David R}",
year = "2004",
month = "2",
language = "English (US)",
volume = "31",
pages = "40--46",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy

AU - Lara, Primo N

AU - Davies, Angela M.

AU - Mack, Philip

AU - Mortenson, Melinda M.

AU - Bold, Richard J

AU - Gumerlock, Paul H.

AU - Gandara, David R

PY - 2004/2

Y1 - 2004/2

N2 - PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.

AB - PS-341 (bortezomib) represents a new class of therapeutics that targets the ubiquitin-proteasome pathway. It has broad-spectrum single-agent anticancer activity and can potentiate chemotherapy and radiation in preclinical models. Early phase clinical studies have shown tolerability and activity in multiple myeloma, lymphoma, prostate cancer, and lung cancers. By its mechanism of inhibiting protein degradation, PS-341 targets a wide range of pathways relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27Kip1, p53, nuclear factor-κB, Bcl-2, and Bax. PS-341 is currently in phase I/II clinical development in both non-small cell lung cancer and small cell lung cancer. This article will review the preclinical and clinical experience with PS-341 as it relates to lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=1242318831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242318831&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 40

EP - 46

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -